Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00557505 · ClinicalTrials.gov registry record · Phase 1
A Study Of PF-03732010 In Patients With Advanced Solid Tumors
A Phase 1 study of Neoplasms, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
- 3
- Study locations
NCT00557505: Completed Phase 1 study of Neoplasms, sponsored by Pfizer.
NCT00557505 is a Phase 1 study of Neoplasms that has completed, run by Pfizer. The registered enrollment target is 43 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00557505, a Phase 1 study of Neoplasms, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
- 3
- Study locations
Study Summary
P-cadherin may play a part in tumor growth; PF-03732010 is a new drug that inhibits P-cadherin. This study will test how well the drug is tolerated, and what effects there might be. Blood will also be taken to measure the amount of drug in blood.
Conditions Studied
Interventions
- DRUG PF-03732010
Study Locations (3)
Pennsylvania
- Pfizer Investigational Site - Philadelphia
Victoria
- Pfizer Investigational Site - Parkville
Other
- Pfizer Investigational Site - Seoul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2007-12 |
| Est. Completion | 2011-02 |
| Phase | Phase 1 |
What the finished NCT00557505 record still lists
NCT00557505 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which PF-03732010 is the first listed.
NCT00557505 reports a single indexed study location in Pennsylvania, Victoria, Other.
Frequently Asked Questions
What is clinical trial NCT00557505 about?
NCT00557505 is a clinical study titled "A Study Of PF-03732010 In Patients With Advanced Solid Tumors". P-cadherin may play a part in tumor growth; PF-03732010 is a new drug that inhibits P-cadherin. This study will test how well the drug is tolerated, and what effects there might be. Blood will also be taken to measure the amount of drug in blood.
What is the current status of trial NCT00557505?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2007-12. Estimated completion is 2011-02.
What conditions does trial NCT00557505 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT00557505?
The interventions under investigation include: PF-03732010 (DRUG).
Who is sponsoring clinical trial NCT00557505?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00557505 being conducted?
This trial has 3 study locations across Pennsylvania, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00557505's enrollment target sits among peer trials
43 115th of 158 higher than 42 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia